1 Reason to Buy Exelixis Stock, and 1 Reason to Sell

Biotech company Exelixis (NASDAQ: EXEL) is not the most famous name in the industry. But quietly, the oncology-focused drugmaker has provided excellent returns this year, even though it's been a bit of a roller-coaster ride.

If Exelixis can continue beating the market, investors would do well to purchase its shares now. But it's not a given that it will. Let's consider one reason the biotech could have a bright future -- and be an excellent investment -- and also why it may not be worth your hard-earned money.

Source Fool.com